Occuity Takes Centre Stage at AECOS Congress London 2025

Innovation is wonderful to behold in all areas of science. Ophthalmology is no exception. Being given the opportunity to deliver a presentation on the incredible work of Occuity was an honour and a privilege.

The event was very well attended by ophthalmologists from the Americas and Europe. It was a pleasure to see so many esteemed clinicians.

I was glad to see Sheraz Daya, the globally renowned ophthalmologist, opening the congress in his role as President of AECOS (American-European Congress of Ophthalmic Surgery).

There were a huge number of companies presenting some very interesting products and innovative developments. We were proud to be the second company to present to the delegates. An expert panel of experienced ophthalmologists and ‘ophthalpreneurs’ were on hand to ask questions and moderate the day’s proceedings.

The focus of my presentation was on the ophthalmic products being developed by Occuity.

Firstly, I discussed the PM1, a handheld, non-contact, optical pachymeter. Easy to use and sustainable, with wireless charging and no need for sterilisation, it will bring convenience to ophthalmology and optometry clinics.

The technology that came from producing the PM1 has led to an array of patented discoveries in optics. From this, Occuity have developed the AX1.

This handheld, non-contact, optical biometer will transform myopia management around the world.

Accurate, repeatable and easy to use, the AX1 provides rapid results. Comparing favourably with expensive desktop based optical biometers, the AX1 will allow repeatable and swift axial length measurements on children and adults. Even very young children can be measured.

Future ophthalmic developments will include an optical biometer capable of measuring corneal centre thickness, anterior chamber depth, lens thickness, axial length and very likely other ocular parameters, like corneal curvature, for example.

Beyond this, I briefly touched upon the developments being made by the excellent scientific team at Occuity on topics like Oculomics and the epidemiology of progressive myopia.

There were many questions after the presentation, including regarding the likely release date of the AX1 and how promising the range of Occuity developments will be.

I very much hope that we get the opportunity next year to demonstrate further progress in a range of ocular related products and we expect to see considerable growth of sales, especially with the release of the AX1 in the near future.